Cook Medical Makes Its Case For Medicare New-Tech Add-On Payments

20 Feb 2012

Cook is seeking add-on payments for its Zilver PTX drug-eluting peripheral stent and Zenith AAA endovascular graft in 2013, addressing related CMS questions at a Feb. 14 new-technology “town hall” meeting.

Cook Medical Inc. fielded CMS questions regarding two vascular devices for which the firm is seeking Medicare new-technology add-on payments during a Feb. 14 “town hall” meeting at CMS headquarters in Baltimore.

The Medicare agency is weighing evidence in support of add-on payments in fiscal 2013 for Cook’s Zilver PTX drug-eluting peripheral...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Medicare Tricuspid Regurgitation Coverage Decision Big Win For Abbott

15 Jul 2025

• By Brian Bossetta

Medicare beneficiaries with tricuspid regurgitation will now have access to an innovative treatment from Abbott that offers a minimally invasive alternative to open-heart surgery.

European MedTech Keeps Calm Despite US Threats Of 30% Tariffs

14 Jul 2025

• By Amanda Maxwell

MedTech Europe wants the EU to continue its commitment to reach a negotiated tariff solution with the US and measured restraint amid escalating trade tensions.

Ochsner Surgeon In ‘The Big Easy’ Eases Patient’s Pain With Skill And Virtual Reality

11 Jul 2025

• By Brian Bossetta

A surgeon at Ochsner Health in New Orleans was able to successfully remove a rare and dangerous tumor from a patient’s spine using cutting-edge technology that would have otherwise made the procedure too risky.

FDA Commissioner’s Voucher Program Should Include Devices, Transplant Technology Firm Says

10 Jul 2025

• By Elizabeth Orr

The FDA's new Commissioner’s National Priority Voucher program aims to expedite drug approvals significantly. Device firms like XVIVO advocate for a similar initiative for devices, emphasizing the potential for faster reviews and improved patient access to lifesaving technologies.